Back to search results

Immunotherapy and Liver Procedures for Liver Cancer (HCC)

This study is testing if combining two immunotherapy drugs, tremelimumab and durvalumab (called the STRIDE regimen), with a liver-directed tumor treatment (LRT) can safely and effectively shrink liver cancer (hepatocellular carcinoma, HCC). LRT can be TACE, TARE, or RFA, which are procedures to treat tumors directly in the liver. The main goal is to see if this combination can reduce the cancer to a stage (Milan Criteria) where a liver transplant might be possible for patients whose cancer is currently too advanced (beyond UCSF criteria). You may be able to join if you are 18 or older, have HCC beyond UCSF criteria, and a life expectancy of at least 12 months. The study plans to enroll 41 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 41 participants. It is testing a specific treatment combination.
What's involved
You would receive immunotherapy through an IV, starting with tremelimumab and durvalumab, and then potentially continuing with durvalumab for up to 12 cycles. You would also undergo a liver-directed tumor treatment (TACE, TARE, or RFA).
Compensation
Not stated in the trial record.
Follow-up
The main outcome will be measured at 12 months after the start of the STRIDE treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07489976

IIT2025-03-YANG-LIFT-HCC

Recruiting
PHASE2Ages 18+InterventionalTreatment
Ju Dong Yang
~41 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants downstaged from beyond UCSF criteria to within Milan criteria by radiographic assessment
Measured over 12 month

Conditions

Hepato Cellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT07489976

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars Sinai

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ju Dong Yang, MD
[email protected]
310-423-6000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

1- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC.
Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible.
Participants who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

What this trial measures

  • Proportion of participants downstaged from beyond UCSF criteria to within Milan criteria by radiographic assessment12 month

    The primary outcome is the proportion of enrolled participants with hepatocellular carcinoma who are successfully downstaged from disease burden exceeding UCSF criteria at baseline to within Milan criteria within 12 months after initiation of STRIDE-based therapy and locoregional treatment. Downstaging status will be determined by follow-up contrast-enhanced CT or MRI using the study's predefined imaging assessment criteria.